Literature DB >> 31138493

Harmonizing care for rare diseases: How we developed the mitochondrial care network in the United States.

Amel Karaa1, Amy Goldstein2, Cristy Balcells3, Kira Mann3, Laura Stanley4, Philip E Yeske5, Sumit Parikh6.   

Abstract

The mitochondrial medicine society (MMS) has previously highlighted the clinical landscape and physician practice patterns of mitochondrial medicine in the US and attempted to develop consensus criteria for diagnosis and management to improve patient coordinated care. Most recently, and in collaboration with US-based patient advocacy groups, we developed a clinical care network to formally unify US-based clinicians who provide medical care to individuals with mitochondrial disease; to define, design and implement best practices in mitochondrial medicine building on the current consensus guidelines and to improve patients' clinical outcomes. Here we review the steps taken in collaboration with several stakeholders to develop goals and expectations for a mitochondrial care network (MCN), criteria for MCN site selection and formal launch of the network.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Care center, harmonizing care; Mitochondrial advocacy group; Mitochondrial medicine society; Primary mitochondrial disease

Mesh:

Year:  2019        PMID: 31138493     DOI: 10.1016/j.ymgme.2019.05.012

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  2 in total

1.  Knowledge and awareness of mitochondrial diseases among physicians in the tertiary hospitals in Ghana.

Authors:  Eric A Mensah; Bismark Sarfo; Alfred E Yawson; Joshua Arthur; Augustine Ocloo
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

Review 2.  Gaining Insight into Mitochondrial Genetic Variation and Downstream Pathophysiology: What Can i(PSCs) Do?

Authors:  Jesse D Moreira; Deepa M Gopal; Darrell N Kotton; Jessica L Fetterman
Journal:  Genes (Basel)       Date:  2021-10-22       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.